Featured

Cleaner, More Flexible Operations and Better Communication: CGT’s Next Breakthrough

Manufacturing is now a biotech strategy problem, not a vendor problem.

CAR-T Platform Moves Novel Therapies from Gene Sequence to Clinic-ready in Under 12 Months

CAR-T has a geography problem

Outsourced Pharma Capacity Update October 2025: Cell & Gene Therapy

Fulfilling The Promise Of Advanced Therapies And A Noble Cause

Rethinking Lentiviral Manufacturing for Cell and Gene Therapies: from Platform Design to Point-of-care Delivery

Strategies for Efficiency and Affordability in Cell and Gene Therapy

Vector BioMed COO Mike Kadan on Reinventing Viral Vector Manufacturing for a Decentralized Gene Therapy Future

Global Access to Cell and Gene Therapy: ARM Studios Interview with Boro Dropulić

Scroll to Top